Reshape Lifesciences Inc. Stock Price, News & Analysis

Vyome Therapeutics has received Nasdaq approval for its merger with ReShape Lifesciences (NASDAQ:RSLS). The combined company will begin trading as Vyome Holdings (NASDAQ:HIND) on August 15, 2025. In conjunction with the merger, ReShape announced a 1-for-4 reverse stock split of its common stock, effective on the same date.

The company focuses on immuno-inflammatory and rare diseases, targeting a market exceeding $100B. Led by Chairman Krishna Gupta and founder Shiladitya Sengupta, Vyome aims to leverage its clinical-stage assets in the immuno-inflammatory space, combining expertise in science and AI with US-India business opportunities.

Vyome Therapeutics announced its new Board of Directors ahead of its public listing through ReShape Lifesciences (NASDAQ: RSLS) on August 15, 2025. The company will be renamed to Vyome Holdings and trade under the ticker symbol HIND.

The newly appointed board consists of six members with strong MIT ties and expertise in AI, healthcare, and the Indian market. Notable appointments include Krishna Gupta as Chairman, Shiladitya Sengupta as Founder, and Venkat Nelabhotla as Co-founder and CEO. The company emphasizes a clean financial structure with no debt, no toxic structure, and locked-up major shareholders.

ReShape Lifesciences (Nasdaq: RSLS) announced that shareholders have approved the merger with Vyome Therapeutics. The merger is set to become effective on August 15, 2025, coinciding with India's Independence Day. The combined company will be renamed to Vyome Holdings, Inc. and will trade under the new symbol "HIND" on the Nasdaq Capital Market.

The transaction includes the sale of ReShape's assets to Biorad Medisys. Vyome aims to establish a healthcare platform focusing on the US-India innovation corridor. Maxim Group LLC and Chardan are serving as financial advisors for ReShape and Vyome respectively, with Fox Rothschild LLP and Sichenzia Ross Ference Carmel LLP acting as legal counsel.

ReShape Lifesciences (Nasdaq: RSLS) announced a partial adjournment of its Special Meeting of Stockholders specifically for two critical proposals. The meeting will reconvene on August 7, 2025 to vote on Proposal 2 (Asset Sale Proposal) and Proposal 3 (Charter Amendment Proposal).

The Asset Sale Proposal involves the sale of substantially all ReShape's assets to Ninjour Health International Limited, while the Charter Amendment Proposal relates to amendments needed for the proposed merger with Vyome Therapeutics. Both proposals are essential conditions for completing the merger. All other merger-related proposals were successfully approved by stockholders.

The company urges all stockholders of record as of June 9, 2025 to vote in favor of these proposals, emphasizing their importance for maximizing stockholder value through the merger completion.

ReShape Lifesciences (Nasdaq: RSLS) announced its inaugural Lap-Band® Surgeon Summit, scheduled for August 1-3, 2025, in Nashville, Tennessee. The summit will be directed by Dr. Christine Ren-Fielding, Professor of Surgery at NYU Grossman School of Medicine, and will host over 20 leading Lap-Band® surgeons.

The event will focus on the benefits of both the original Lap-Band® and the next-generation Lap-Band® 2.0 FLEX, exploring the role of GLP-1s in patient care and strategies for patient education. The company has reported positive early feedback from the limited U.S. market release of the Lap-Band® 2.0 FLEX, which features self-adjusting technology designed to work alongside medical therapies like GLP-1s.

ReShape Lifesciences (NASDAQ: RSLS) has announced a Special Meeting of Stockholders scheduled for July 24, 2025 to vote on crucial proposals regarding a strategic transformation. The company's Board unanimously recommends shareholders approve a merger with Vyome Therapeutics, a clinical-stage company focused on immuno-inflammatory and rare diseases, alongside a concurrent sale of ReShape's assets to Biorad Medisys.

Shareholders will vote on three key proposals: (1) issuance of common stock shares, (2) approval of the asset sale, and (3) amendments to the certificate of incorporation for post-closing board composition. Both independent proxy advisory firms ISS and Glass Lewis have recommended voting in favor of all proposals.

The transaction aims to create a debt-free entity focused on immune-inflammatory assets development, leveraging U.S.-India innovation synergies.

ReShape Lifesciences (Nasdaq: RSLS) announced the upcoming issuance of U.S. Patent 12,350,179 by the USPTO on July 8, 2025, covering their intragastric balloon system. The patent specifically protects a swallowable capsule design featuring a self-sealing fill valve and degradable release valve that deflates after three months for natural excretion.

The patent will provide protection until at least January 2031, with potential for extension. CEO Paul F. Hickey highlighted that the company has built a substantial intellectual property portfolio, including over 50 patents specifically for their intragastric balloon technology and a total of over 160 issued and pending patents across various proprietary technologies.

ReShape Lifesciences (Nasdaq: RSLS), a weight loss and metabolic health-solutions company, has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement. The company, which was previously at risk of delisting due to having only $1.2 million in stockholders' equity as of March 31, 2025, has now met the required $2.5 million minimum.

To achieve compliance, ReShape completed two key transactions: an at-the-market offering of 593,000 shares raising $3.64 million, and a subsequent offering of 1,054,604 shares generating $2.64 million in gross proceeds. These actions have resolved the listing concern, and Nasdaq has officially closed the matter.

ReShape Lifesciences (NASDAQ:RSLS) announced strategic cost reductions and updates on pending transactions. The company is implementing a workforce reduction expected to save over $750,000 annually, representing 23.4% of payroll expenses, while maintaining its sales and marketing team intact.

The company is progressing with its merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys. A special shareholder meeting is scheduled for July 24, 2025 to vote on these strategic transactions. The Board of Directors has unanimously endorsed these deals, viewing them as transformative opportunities for long-term value creation.